Neuphoria Therapeutics Inc. (NEUP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Sep 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NEUP SEC filings page.
Neuphoria Therapeutics Inc. (NEUP) reported $1.2M in revenue for fiscal year 2026, down 92.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing dependence remains central as revenue contracted and fixed operating costs pushed losses back into cash outflow.
Revenue fell from$15.6M in FY2025 to$1.2M in FY2026, while the operating loss widened sharply, showing that costs did not flex down with the smaller business. Operating cash flow also swung from$77K positive to$12.4M of operating cash burn, linking the earnings deterioration to actual cash consumption rather than an accounting-only result.
The balance sheet became less liability-heavy: total liabilities declined from
FY2025's operating cash flow of
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Neuphoria Therapeutics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Neuphoria Therapeutics Inc. held $19.9M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $12.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Neuphoria Therapeutics Inc. scores 45/100 among other emerging companies.
Neuphoria Therapeutics Inc. had 5M shares outstanding at the end of fiscal year 2026. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Neuphoria Therapeutics Inc. scores 99/100 among other emerging companies.
Not available for Neuphoria Therapeutics Inc., and counted as zero in the overall score.
Neuphoria Therapeutics Inc. reported revenue of $1.2M in fiscal year 2026, against $15.6M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Neuphoria Therapeutics Inc. scores 1/100 among other emerging companies.
Neuphoria Therapeutics Inc.'s operations used $12.4M of cash in fiscal year 2026, against $77K generated in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Neuphoria Therapeutics Inc. scores 55/100 among other emerging companies.
Neuphoria Therapeutics Inc.'s cash, cash equivalents and investments came to $19.9M at the end of fiscal year 2026, against $4.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Neuphoria Therapeutics Inc. scores 89/100 among other emerging companies.
Neuphoria Therapeutics Inc. scores -7.63, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($18.7M) relative to total liabilities ($4.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Neuphoria Therapeutics Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Neuphoria Therapeutics Inc. reported a net loss of $13.5M while operations used $12.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Neuphoria Therapeutics Inc. earned -$0.95 per diluted share (EPS) in Q4 2026. Against the prior quarter it is down 955.6%.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
Neuphoria Therapeutics Inc. held $19.9M in cash as of Q4 2026; long-term debt is not reported for that period.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
None of these metrics is reported for Q4 2026.
NEUP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $15.0M | $663K | N/A |
| R&D Expenses | N/A | N/A | $698K-59.8% | $3.8M+99.2% | N/A | $1.6M+34.8% | $1.7M-14.6% | $1.9M-38.4% |
| SG&A Expenses | N/A | $1.7M+19.9% | $2.1M-19.1% | $1.9M+12.0% | N/A | $1.4M+17.7% | $2.6M+4.4% | $1.7M-29.9% |
| Operating Income | N/A | -$1.2M-110.1% | -$4.1M-9.6% | -$5.7M-58.4% | N/A | $12.0M+600.3% | -$3.7M+18.7% | -$3.6M+34.7% |
| EBITDA | N/A | -$1.0M-108.6% | -$3.9M-10.1% | -$5.5M-61.3% | N/A | $12.1M+644.9% | -$3.5M+19.4% | -$3.4M+35.8% |
| Income Tax | N/A | -$35K+57.1% | -$35K-399.7% | -$35K+73.7% | N/A | -$81K-595.6% | $12K+133.4% | -$132K-279.9% |
| Net Income | N/A | -$505K-104.5% | $1.9M+195.9% | -$9.9M-1130.9% | N/A | $11.3M+505.4% | -$1.9M+57.3% | -$805K+85.3% |
| EPS (Basic) | -$0.95+83.6% | -$0.09-101.4% | $0.41+133.3% | -$4.41-611.3% | -$5.79-69.3% | $6.55+331.4% | -$1.23+76.8% | -$0.62 |
| EPS (Diluted) | -$0.95 | -$0.09 | -$0.77 | -$4.41 | -$5.79 | $6.55 | -$1.79+66.3% | -$0.62 |
| Diluted Shares (Avg) | N/A | 5M | 5M | 2M | N/A | 2M | 2M+83.8% | 1M-99.9% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
NEUP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $28.7M+0.4% | $34.8M+13.3% | $36.6M+101.4% | $27.3M+19.3% | $28.6M+3.4% | $30.7M | $18.2M | $22.9M |
| Current Assets | $21.1M+40.1% | $21.7M+26.7% | $23.4M+431.7% | $14.0M+65.5% | $15.0M+14.0% | $17.1M | $4.4M | $8.4M |
| Cash & Equivalents | $19.9M+39.8% | $19.4M+14.1% | $22.2M+410.3% | $13.6M+68.9% | $14.2M+12.7% | $17.0M+102.3% | $4.3M-57.2% | $8.1M-0.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $813K+6708.1% | $1.6M+6427.9% | $1.1M+3021.1% | $2K-98.5% | $12K-90.6% | $25K | $36K | $116K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $3.5M-59.5% | $8.8M+4.6% | $8.7M+3.9% | $8.7M-2.6% | $8.6M-0.6% | $8.5M-2.0% | $8.4M-4.9% | $8.9M+3.8% |
| Total Liabilities | $4.1M-57.1% | $5.4M+14.2% | $6.9M+56.0% | $14.8M+153.7% | $9.6M-5.6% | $4.7M | $4.4M | $5.8M |
| Current Liabilities | $757K-82.1% | $1.5M-2.5% | $2.6M+21.2% | $5.1M+100.8% | $4.2M+10.2% | $1.6M | $2.1M | $2.6M |
| Non-Current Liabilities | $3.4M-37.5% | $3.9M+22.4% | $4.3M+88.5% | $9.7M+194.7% | $5.4M-15.2% | $3.2M | $2.3M | $3.3M |
| Total Equity | $24.6M+29.5% | $29.4M+13.2% | $29.7M+116.0% | $12.5M-26.7% | $19.0M+8.6% | $26.0M+44.9% | $13.7M-29.5% | $17.1M-0.9% |
| Retained Earnings | -$191.8M-7.5% | -$186.9M-10.3% | -$186.4M-3.1% | -$188.3M-5.3% | -$178.3M-0.2% | -$169.5M | -$180.7M | -$178.8M |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
NEUP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.2M+133.9% | -$3.3M-129.1% | -$6.4M-91.7% | -$3.8M+14.4% | -$3.6M-19.1% | $11.5M+447.6% | -$3.4M+14.9% | -$4.4M-0.1% |
| Depreciation & Amortization | $166K0.0% | $166K+0.2% | $166K-0.2% | $166K0.0% | $166K0.0% | $165K-0.2% | $166K+0.3% | $166K-0.1% |
| Stock-Based Compensation | N/A | N/A | N/A | $111K+316.2% | N/A | N/A | N/A | $27K-79.9% |
| Financing Cash Flow | $0-100.0% | $0-100.0% | $14.7M+13242.7% | $3.3M+1531.2% | $705K-90.1% | $1.2M-33.5% | -$112K-102.0% | -$227K-137.1% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
NEUP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | 79.8% | -558.8% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 75.1% | -293.2% | N/A |
| Return on Equity | N/A | -1.7%-45.0pp | 6.3%+20.4pp | -79.2%-74.5pp | N/A | 43.3%+58.8pp | -14.1%+9.2pp | -4.7%+27.1pp |
| Return on Assets | N/A | -1.5%-38.1pp | 5.1%+15.8pp | -36.2%-32.7pp | N/A | 36.7% | -10.7% | -3.5% |
| Current Ratio | 27.85+24.3x | 14.31+3.3x | 9.04+7.0x | 2.72-0.6x | 3.56+0.1x | 11.01 | 2.06 | 3.30 |
| Debt-to-Equity | 0.17-0.3x | 0.180.0x | 0.23-0.1x | 1.19+0.8x | 0.50-0.1x | 0.18 | 0.32 | 0.34 |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | 0.49 | 0.04 | N/A |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. NEUP | FY2026 | $1.2M | -$13.5M | N/A | $18.7M | 48/100 |
| Kezar Life Sciences, Inc. KZR | FY2025 | $0 | -$56.0M | N/A | $53.9M | — |
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $15.9M | — |
| Boundless Bio, Inc. BOLD | FY2025 | N/A | -$58.2M | N/A | $59.1M | — |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $71.2M | — |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $20.4M | — |
Where Neuphoria Therapeutics Inc. Ranks
Frequently Asked Questions
What is Neuphoria Therapeutics Inc.'s annual revenue?
Neuphoria Therapeutics Inc. (NEUP) reported $1.2M in total revenue for fiscal year 2026. This represents a -92.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Neuphoria Therapeutics Inc.'s revenue growing?
Neuphoria Therapeutics Inc. (NEUP) revenue declined by 92.5% year-over-year, from $15.6M to $1.2M in fiscal year 2026.
Is Neuphoria Therapeutics Inc. profitable?
No, Neuphoria Therapeutics Inc. (NEUP) reported a net income of -$13.5M in fiscal year 2026.
What is Neuphoria Therapeutics Inc.'s EBITDA?
Neuphoria Therapeutics Inc. (NEUP) had EBITDA of -$15.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Neuphoria Therapeutics Inc.'s return on equity (ROE)?
Neuphoria Therapeutics Inc. (NEUP) has a return on equity of -54.7% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Neuphoria Therapeutics Inc.'s operating cash flow?
Neuphoria Therapeutics Inc. (NEUP) recorded an outflow of $12.4M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Neuphoria Therapeutics Inc.'s total assets?
Neuphoria Therapeutics Inc. (NEUP) had $28.7M in total assets as of fiscal year 2026, including both current and long-term assets.
What is Neuphoria Therapeutics Inc.'s current ratio?
Neuphoria Therapeutics Inc. (NEUP) had a current ratio of 27.85 as of fiscal year 2026, which is generally considered healthy.
What is Neuphoria Therapeutics Inc.'s debt-to-equity ratio?
Neuphoria Therapeutics Inc. (NEUP) had a debt-to-equity ratio of 0.17 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neuphoria Therapeutics Inc.'s return on assets (ROA)?
Neuphoria Therapeutics Inc. (NEUP) had a return on assets of -46.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Neuphoria Therapeutics Inc.'s P/E ratio?
Neuphoria Therapeutics Inc. (NEUP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $18.7M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Neuphoria Therapeutics Inc.'s price-to-sales ratio?
Neuphoria Therapeutics Inc. (NEUP) trades at 15.9x sales, its market capitalization divided by revenue of $1.2M revenue, FY2026. The market capitalization is $18.7M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Neuphoria Therapeutics Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Neuphoria Therapeutics Inc. (NEUP) held $19.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.4M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Neuphoria Therapeutics Inc.'s Altman Z-Score?
Neuphoria Therapeutics Inc. (NEUP) has an Altman Z-Score of -7.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Neuphoria Therapeutics Inc.'s Piotroski F-Score?
Neuphoria Therapeutics Inc. (NEUP) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neuphoria Therapeutics Inc.'s earnings high quality?
Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $13.5M while operations used $12.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Neuphoria Therapeutics Inc.?
Neuphoria Therapeutics Inc. (NEUP) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.